Univariable logistic regression of treatment regimen and associated factors as predictors of negative outcomes
| Overall n (column %) | Negative outcome n (row %) | OR (95% CI) | p-value | |
| Overall | 538 (100) | 84 (15.6) | ||
| Regimen | ||||
| (H)RfZE | 306 (56.9) | 46 (15.0) | 0.93 | |
| (H)RfZE-Fq/M | 192 (35.7) | 30 (15.6) | 1.02 (0.59–1.77) | |
| Missing | 40 (7.4) | 8 (20.0) | ||
| Thrice-weekly dosing | ||||
| More frequent | 464 (86.2) | 66 (14.2) | 0.15 | |
| Thrice weekly | 53 (9.9) | 12 (22.6) | 1.81 (0.83–3.94) | |
| Missing | 21 (3.9) | 6 (28.6) | ||
| Time before Hr known | ||||
| 0 to <2 months | 325 (60.4) | 56 (17.2) | 0.27 | |
| 2 to <6 months | 159 (29.6) | 18 (11.3) | 0.62 (0.34–1.13) | |
| ≥6 months | 10 (1.9) | 2 (20.0) | 1.11 (0.22–5.66) | |
| Missing | 44 (8.2) | 8 (18.2) | ||
| Phenotype | ||||
| Highly resistant | 442 (82.2) | 69 (15.6) | 0.73 | |
| Resistant | 36 (6.7) | 5 (13.9) | 0.88 (0.32–2.39) | |
| Borderline, sensitive or results not logged | 29 (5.4) | 6 (20.7) | 1.46 (0.55–3.88) | |
| Missing | 31 (5.8) | 4 (12.9) | ||
| Adherence issues or treatment gaps | ||||
| No or unknown | 425 (79.0) | 64 (15.1) | 0.29 | |
| Not severe or of unknown severity | 56 (10.4) | 13 (23.2) | 1.62 (0.80–3.28) | |
| Severe | 57 (10.6) | 7 (12.3) | 0.72 (0.30–1.73) |
Univariable logistic regression of treatment regimen and associated factors as predictors of negative regimen-specific outcomes. Included patients were notified in London, had regimen-specific outcome and regimen information, and their disease was without additional drug resistance, unless to streptomycin. Each model contains the patients without missing data. H: isoniazid; Rf: rifamycin; Z: pyrazinamide; E: ethambutol; Fq: fluoroquinolones; M: moxifloxacin; Hr: isoniazid resistance.